We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA awarded clinical trial grants, totaling more than $23 million over four years, for research on 21 rare diseases, including amyotrophic lateral sclerosis, brain tumors, cystic fibrosis and drug-resistant HIV. Read More
The United Nations High-Level Panel on Access to Medicine is proposing that governments rely on compulsory licenses to improve patient access to medicines in a highly anticipated report that has been met with dismay from industry. Read More
A joint meeting of three FDA advisory committees tackled the issue of prescribing opioid painkillers in pediatrics and came up with a constant refrain: We need more data. Read More
Diabetes drugs carry special development challenges and can be the riskiest sector in pharmaceuticals, with one in 13 investigational drugs achieving U.S. approval, according to a report from the Tufts Center for the Study of Drug Development. Read More
The FDA confirmed the use of total kidney volume measurements in selecting patients for clinical trials in autosomal dominant polycystic kidney disease. Read More
Kite Pharma announced positive interim results from a Phase II clinical trial of its immunotherapy in patients with aggressive non-Hodgkin’s lymphomas and said the study would form the basis of its marketing submissions to the FDA. Read More
Three pharmaceutical companies announced Phase III trial results from their injectable psoriasis treatments — with one delivering better head-to-head clinical results than international top-selling drug Humira, which reached over $14 billion in sales in 2015. Read More